ZIA CP010206-10383 (ZIA) | |||
---|---|---|---|
Title | The HPV Persistence and Progression Cohort (PaP Cohort) | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Schiffman, Mark | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $292,453 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Cervical Cancer (100.0%) | ||
Research Type | |||
Technology Development and/or Marker Discovery Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis |
|||
Abstract | |||
"The carcinogenicity of the dozen HPV types with carcinogenic potential varies greatly. We wish to increase the already proven clinical utility of carcinogenic HPV DNA testing in women 30 and older by understanding the unique properties of individual HPV types for viral persistence and progression. Specifically, we seek to understand the timing and determinants of viral clearance versus persistence and, give persistence, the risk of progression to CIN3/cancer among women infected with each type of carcinogenic HPV at the ages when cancer occurs. The relevant natural history data are lacking. There are no NCI or other cohorts in which these and other questions are being adequately addressed. Kaiser Permanente Northern California (KPNC) routinely uses a FDA-approved pooled-type DNA test for carcinogenic HPV (Hybrid Capture 2 [HC2], Digene Corporation, Gaithersburg, MD) as an adjunct to cytology for cervical cancer screening in women 30 and older. We will team with KPNC to create a carcinogenic HPV-HPV genotypes. Specifically, we will store approximately 35,000 baseline specimens that have tested positive by HC2 and 5,000 specimens that have tested negative by HC2. A final group of women are under age 30 and were HPV tested for triage of equivocal cytology. We will use efficient sampling designs to achieve high power with minimal laboratory analyses, with specimens selected for testing based on clinical outcomes ascertained by linkage to the kaiser cytology and histology databases and KPNC's active yearly follow-up of all HC2-positive women. We plan to ""follow"" women for 3 years after their enrollment in 2007-11 by banking their residual specimens collected at their return visits. The study has now turned into a passively followed cohort study. A small contract was completed to obtain epidemiologic co-factor data for all of the cohort members." |